Jiménez Galán, R., Prado-Mel, E., Álvarez de Sotomayor Paz, M., & Abdel-Kader Martín, L. (2023). Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer.
Citación estilo ChicagoJiménez Galán, Rocío, Elena Prado-Mel, María Álvarez de Sotomayor Paz, y Laila Abdel-Kader Martín. Impact of Frailty On Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population With Advanced Non-Small Cell Lung Cancer. 2023.
Cita MLAJiménez Galán, Rocío, Elena Prado-Mel, María Álvarez de Sotomayor Paz, y Laila Abdel-Kader Martín. Impact of Frailty On Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population With Advanced Non-Small Cell Lung Cancer. 2023.